Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid ...
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoi...
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 61
- Registration Number
- NCT00321932
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States
Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2014-08-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 416
- Registration Number
- NCT00320710
- Locations
- 🇺🇸
Greenbaum Cancer Center, Baltimore, Maryland, United States
🇺🇸U of Pittsburgh Cancer Institute Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Frederick Memorial Hospital, Frederick, Maryland, United States
A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 2049
- Registration Number
- NCT00321464
Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries
- Conditions
- Interventions
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 160
- Registration Number
- NCT00305695
- Locations
- 🇺🇸
University of Illinois, Chicago, Illinois, United States
🇺🇸Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸University of California San Diego, San Diego, California, United States
Use of Bisphosphonates in the Treatment of Osteopathy After Liver Transplantation
- Conditions
- First Posted Date
- 2006-03-14
- Last Posted Date
- 2006-07-26
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 96
- Registration Number
- NCT00302484
- Locations
- 🇦🇹
Medical University of Vienna, Department of Surgery, Division of Transplantation, Vienna, Austria
S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone
- Conditions
- Interventions
- First Posted Date
- 2006-03-13
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00301886
Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation
- Conditions
- Interventions
- First Posted Date
- 2006-03-01
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 111
- Registration Number
- NCT00297830
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
- Conditions
- Interventions
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Austrian Breast & Colorectal Cancer Study Group
- Target Recruit Count
- 1803
- Registration Number
- NCT00295646
- Locations
- 🇦🇹
State Hospital Klagenfurt, Surgery, Klagenfurt, Carinthia, Austria
🇦🇹State Hospital Klagenfurt, Klagenfurt, Carinthia, Austria
🇩🇪Medical University Kiel, Kiel, Schleswig-Holstein, Germany
Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 45
- Registration Number
- NCT00295867
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM)
- First Posted Date
- 2006-02-06
- Last Posted Date
- 2014-12-09
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 17
- Registration Number
- NCT00287261
- Locations
- 🇮🇱
RAMBAM Medical Center and Technion, Haifa, Israel
🇦🇺Cancer Care Services, Brisbane, Queensland, Australia
🇫🇷Hopital Avicenne and Paris 13 University, Bobigny, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.